Bompart G, Puig P, Pipy B, Béraud M, Souqual M C
INSERM U 133, Toulouse, France.
J Toxicol Environ Health. 1989;26(4):459-68. doi: 10.1080/15287398909531269.
Our study presents the in vitro molybdenum influence on benzo[a]pyrene (BaP) microsomal metabolism. Addition of various concentrations of different molybdenum salts [MoS2, MoCl5, (NH4)6Mo7O24 . 4H2O] to liver and lung microsomal fractions of rats previously treated with 3-methylcholanthrene produces a decrease in the different BaP metabolites assessed by high-performance liquid chromatography (HPLC) analysis. This inhibition varies, depending on the considered metabolite and in relation to both the molybdenum level and the origin of the microsomal suspension. The minimum effective concentration is 0.26 and 0.52 mM Mo from liver and lung, respectively. The inhibitory potencies of the +5 (chloride) and +6 (ammonium heptamolybdate) molybdenum compounds are comparable; that of the sulfide is lower.
我们的研究展示了体外钼对苯并[a]芘（BaP）微粒体代谢的影响。向先前用3-甲基胆蒽处理过的大鼠肝脏和肺微粒体组分中添加不同浓度的各种钼盐[二硫化钼、五氯化钼、（NH4）6Mo7O24·4H2O]，通过高效液相色谱（HPLC）分析评估发现，不同的BaP代谢产物有所减少。这种抑制作用因所考虑的代谢产物不同而有所变化，并且与钼水平以及微粒体悬浮液的来源有关。肝脏和肺中钼的最低有效浓度分别为0.26 mM和0.52 mM。+5价（氯化物）和+6价（钼酸铵）钼化合物的抑制效力相当；硫化物的抑制效力较低。
